Fortress Biotech Sees Upgrades Amid Investor Shifts
"Fortress Biotech (FBIO) upgraded to 'Hold' by StockNews.com amid 5.8% decline; analysts offer mixed ratings as hedge funds increase stakes."
- Latest
- Trending
"Fortress Biotech (FBIO) upgraded to 'Hold' by StockNews.com amid 5.8% decline; analysts offer mixed ratings as hedge funds increase stakes."
Cidara Therapeutics receives $11.1 million milestone payment from Mundipharma for European approval of new antifungal drug, Rezzayo. Analysts see potential ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.